JP2014510518A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510518A5 JP2014510518A5 JP2013553420A JP2013553420A JP2014510518A5 JP 2014510518 A5 JP2014510518 A5 JP 2014510518A5 JP 2013553420 A JP2013553420 A JP 2013553420A JP 2013553420 A JP2013553420 A JP 2013553420A JP 2014510518 A5 JP2014510518 A5 JP 2014510518A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- hsa
- substitution
- amino acid
- fcrn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 39
- 229920001184 polypeptide Polymers 0.000 claims 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims 38
- 102000008100 Human Serum Albumin Human genes 0.000 claims 25
- 108091006905 Human Serum Albumin Proteins 0.000 claims 25
- 238000006467 substitution reaction Methods 0.000 claims 19
- 235000018102 proteins Nutrition 0.000 claims 14
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 235000001014 amino acid Nutrition 0.000 claims 12
- 150000001413 amino acids Chemical group 0.000 claims 12
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 11
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 6
- 229960000310 isoleucine Drugs 0.000 claims 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000004471 Glycine Substances 0.000 claims 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 4
- 239000004473 Threonine Substances 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 235000009582 asparagine Nutrition 0.000 claims 3
- 229960001230 asparagine Drugs 0.000 claims 3
- 235000018417 cysteine Nutrition 0.000 claims 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 230000005714 functional activity Effects 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/024855 WO2011103076A1 (en) | 2010-02-16 | 2011-02-15 | Hsa-related compositions and methods of use |
| USPCT/US2011/024855 | 2011-02-15 | ||
| PCT/US2011/047040 WO2012112188A1 (en) | 2011-02-15 | 2011-08-09 | Hsa-related compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014510518A JP2014510518A (ja) | 2014-05-01 |
| JP2014510518A5 true JP2014510518A5 (https=) | 2014-09-04 |
Family
ID=46675795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553420A Pending JP2014510518A (ja) | 2011-02-15 | 2011-08-09 | Ｈｓａ関連組成物および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2675471A4 (https=) |
| JP (1) | JP2014510518A (https=) |
| KR (1) | KR20140012094A (https=) |
| CN (1) | CN103379915A (https=) |
| AU (1) | AU2011359378A1 (https=) |
| CA (1) | CA2826683A1 (https=) |
| WO (1) | WO2012112188A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101722961B1 (ko) | 2009-02-11 | 2017-04-04 | 알부메딕스 에이/에스 | 알부민 변이체 및 접합체 |
| CA2776241A1 (en) | 2009-10-30 | 2011-05-05 | Novozymes Biopharma Dk A/S | Albumin variants |
| CA2789337A1 (en) * | 2010-02-16 | 2011-08-25 | Medimmune, Llc | Hsa-related compositions and methods of use |
| US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
| US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
| JP6187777B2 (ja) | 2011-06-13 | 2017-08-30 | シーエスエル、リミテッド | Ｇ−ｃｓｆｒに対する抗体およびその使用 |
| EP2780364A2 (en) * | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| WO2013135896A1 (en) | 2012-03-16 | 2013-09-19 | Novozymes Biopharma Dk A/S | Albumin variants |
| MX2015005363A (es) | 2012-11-08 | 2015-11-06 | Novozymes Biopharma Dk As | Variantes de albumina. |
| AU2014217831A1 (en) | 2013-02-16 | 2015-07-16 | Albumedix Ltd. | Pharmacokinetic animal model |
| ES2660912T3 (es) * | 2013-03-15 | 2018-03-26 | Affibody Ab | Nuevos polipéptidos |
| ES2699576T3 (es) | 2013-06-12 | 2019-02-11 | Pharis Biotec Gmbh | Péptidos con actividades antagonistas contra CXCR4 natural |
| WO2015036579A1 (en) * | 2013-09-13 | 2015-03-19 | Novozymes Biopharma Dk A/S | Albumin variants |
| US10208102B2 (en) | 2013-11-01 | 2019-02-19 | University Of Oslo | Albumin variants and uses thereof |
| EP3842451A1 (en) | 2015-03-12 | 2021-06-30 | MedImmune, LLC | Method of purifying albumin-fusion proteins |
| WO2017029407A1 (en) | 2015-08-20 | 2017-02-23 | Albumedix A/S | Albumin variants and conjugates |
| EP3708580B1 (en) * | 2015-09-23 | 2023-11-01 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type iii domains |
| JP7146637B2 (ja) | 2015-12-22 | 2022-10-04 | アルブミディクス リミティド | 改善されたタンパク質発現株 |
| EP3394243A1 (en) | 2015-12-22 | 2018-10-31 | Albumedix Ltd. | Improved protein expression strains |
| CN110337590A (zh) | 2016-11-04 | 2019-10-15 | 奥胡斯大学 | 以新生儿Fc受体过表达为特征的肿瘤的识别和治疗 |
| JP7282693B2 (ja) | 2017-06-20 | 2023-05-29 | アルブミディクス リミティド | 改良されたタンパク質発現株 |
| CA3081770A1 (en) | 2017-11-29 | 2019-06-06 | Csl Limited | Method of treating or preventing ischemia-reperfusion injury |
| WO2019178645A1 (en) | 2018-03-23 | 2019-09-26 | Csl Limited | Method of treating asthma |
| SI3793586T1 (sl) | 2018-05-16 | 2024-07-31 | Csl Limited | Različice receptorja za topni komplement tipa 1 in njihova uporaba |
| CN113508135A (zh) | 2018-10-29 | 2021-10-15 | 比奥根Ma公司 | 增强血脑屏障转运的人源化和稳定化的fc5变体 |
| CN114341195B (zh) | 2019-09-06 | 2025-04-25 | 诺华股份有限公司 | 治疗性融合蛋白 |
| EP4069200A1 (en) | 2019-12-04 | 2022-10-12 | Albumedix Ltd | Methods and compositions produced thereby |
| US12583929B2 (en) | 2020-06-04 | 2026-03-24 | CSL Innovation Pty Ltd | Method of treating acute respiratory distress syndrome |
| CN114478800B (zh) * | 2021-02-05 | 2022-10-11 | 华南理工大学 | 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用 |
| CN113912730B (zh) * | 2021-12-14 | 2022-03-04 | 北京科诺信诚科技有限公司 | 缓释的抗FcRn抗体或抗原结合片段及其应用 |
| EP4608448A1 (en) | 2022-10-28 | 2025-09-03 | Aarhus Universitet | Albumin conjugated to cpg oligodeoxynucleotides as super-boosters of immune response |
| EP4442251A1 (en) | 2023-04-05 | 2024-10-09 | Albumedix Ltd | Formulations and uses thereof |
| KR20260036321A (ko) | 2023-07-05 | 2026-03-16 | 씨에스엘 이노베이션 피티와이 엘티디 | 겸상적혈구병의 합병증을 치료하거나 예방하는 방법 |
| WO2025158071A1 (en) | 2024-01-26 | 2025-07-31 | Sartorius Albumedix Limited | Retroviral preparations containing albumin for enhancing transduction efficiency, uses thereof for cell transduction |
| EP4703468A1 (en) | 2024-08-29 | 2026-03-04 | Sartorius Albumedix Limited | Methods and uses |
| WO2026074121A1 (en) | 2024-10-02 | 2026-04-09 | Sartorius Albumedix Limited | Albumin formulations and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9404270D0 (en) * | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
| US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
| CA2721093A1 (en) * | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| CN102458442B (zh) * | 2009-04-08 | 2016-06-29 | 加利福尼亚大学董事会 | 具有受控血清药代动力学的人蛋白支架 |
| CA2789337A1 (en) * | 2010-02-16 | 2011-08-25 | Medimmune, Llc | Hsa-related compositions and methods of use |
-
2011
- 2011-08-09 CN CN2011800674634A patent/CN103379915A/zh active Pending
- 2011-08-09 KR KR1020137024189A patent/KR20140012094A/ko not_active Withdrawn
- 2011-08-09 CA CA2826683A patent/CA2826683A1/en not_active Abandoned
- 2011-08-09 AU AU2011359378A patent/AU2011359378A1/en not_active Abandoned
- 2011-08-09 WO PCT/US2011/047040 patent/WO2012112188A1/en not_active Ceased
- 2011-08-09 EP EP11858565.2A patent/EP2675471A4/en not_active Withdrawn
- 2011-08-09 JP JP2013553420A patent/JP2014510518A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510518A5 (https=) | ||
| JP2016052315A5 (https=) | ||
| FI3434767T3 (fi) | Sytotoksisuutta aiheuttava terapeuttinen aine | |
| JP2013517783A5 (https=) | ||
| JP2016512213A5 (https=) | ||
| NZ610075A (en) | Cxcr2 binding polypeptides | |
| JP2018171063A5 (https=) | ||
| JP2013545724A5 (https=) | ||
| JP2017527272A5 (https=) | ||
| JP2015212284A5 (https=) | ||
| WO2015063611A4 (en) | Albumin variants and uses thereof | |
| CA2502904A1 (en) | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis | |
| JP2017512063A5 (https=) | ||
| JP2015504052A5 (https=) | ||
| JP2018521640A5 (https=) | ||
| IL276286B2 (en) | FC variants with improved binding to FCRN and extended half-life | |
| EA036805B8 (ru) | Белок cd24 для подавления ответа хозяина на damp | |
| JP2005120106A5 (https=) | ||
| IL294314B1 (en) | Fibronectin scaffold domain-based proteins that bind to myostatin | |
| JP2015530390A5 (https=) | ||
| JP2015525217A5 (https=) | ||
| JP2013520426A5 (https=) | ||
| JP2010068806A5 (https=) | ||
| JP2002206000A5 (https=) | ||
| JP2018538356A5 (https=) |